Market Size 2023 (Base Year) | USD 52.88 Million |
Market Size 2032 (Forecast Year) | USD 81.33 Million |
CAGR | 4.9% |
Forecast Period | 2024 - 2032 |
Historical Period | 2018 - 2023 |
As per the published report by Market Research Store, the global Carboprost Tromethamine Market size was estimated at USD 52.88 Million in 2023 and is anticipated to reach USD 81.33 Million by 2032, growing at a projected CAGR of 4.9%. The report provides a detailed analysis of the global market, including market trends, market dynamics, and market opportunities during the forecast period (2024-2032). It delves deeper into several market facets, such as market definition, size, growth, forecast, segmentation, competitive analysis, growth drivers, restraints, financial analysis, SWOT analysis, PORTER’s five force analysis, PESTEL analysis, market share analysis, cost-benefit analysis, challenges, restraints, strategic recommendations, and market players.
The global carboprost tromethamine market is expected to expand at a CAGR of 3.9% during the forecast period. Carboprost is a synthesized oxytocic prostalglandin. Carboprost tromethamine is also known as Hemabate, is a kind of prostaglandin that is used to treat excessive bleeding after childbirth in women and postpartum hemorrhage. It's also used as a contraceptive pill to trigger abortion by producing uterine contractions and progressive placental evacuation. The medication is given during the third and fifth months of pregnancy. It causes greater contractions by acting on the F receptor or the E2 receptor sites in the uterus muscles. As a result, the uterus's conception products are evacuated. Additionally, it enhances gastrointestinal stimulation, which can result in nausea and vomiting.
The global carboprost tromethamine market is growing at a rapid rate. A rise in the incidence of postpartum hemorrhage is the major factor that is driving the growth of the market for carboprost tromethamine. In the United States, postpartum hemorrhage is the greatest cause of maternal mortality on the day after birth, accounting for around 11% of all maternal fatalities. Also, as per the study conducted by Stanford Children Health, postpartum hemorrhage affects 1 in 100 to 5 in 100 women. It is more likely to occur in cesarean delivery. Thus, in order to reduce the mortality rate caused by postpartum hemorrhage in developed as well as developing countries, there is a rise in the demand for the use of carboprost tromethamine thereby fueling the market growth.
Further, initiatives taken by the government regarding the use of carboprost tromethamine in rural areas are fostering the market growth. In addition to this, favorable support by regulatory bodies for the approval of the drug is also supporting the growth of the market. Moreover, the growing inclination towards the use of generic drugs and key market players involved in the production of generic drugs of carboprost tromethamine may have numerous opportunities for the growth of the global carboprost tromethamine market during the forecast period. For instance, in March 2021, Sunny Pharmtech Inc. revealed that their Carboprost Tromethamine Injection ANDA ("Abbreviated New Drug Application") is approved by the US FDA on March 26, 2021. However, serious adverse effects related to carboprost tromethamine administration, such as menstruation irregularities, breast soreness, and nausea is limiting the growth of the global carboprost tromethamine market.
The impact of the COVID-19 pandemic on the global carboprost tromethamine market was estimated low to moderate. This is due to the fully operational pharmaceutical sector during the pandemic period. Demand for pharmaceutical products for all the applications remained high, also, the fewer restrictions on transportation of pharmaceutical products maintained the revenue flow for the carboprost tromethamine market.
The global market for carboprost tromethamine is categorized based on type, application, and region.
Based on type, the global market for carboprost tromethamine is bifurcated into 50 ML and below and more than 50 ML.
The application segment of the market is segregated into personal care, pharmaceuticals, and others.
Report Attributes | Report Details |
---|---|
Report Name | Carboprost Tromethamine Market |
Market Size in 2023 | USD 52.88 Million |
Market Forecast in 2032 | USD 81.33 Million |
Growth Rate | CAGR of 4.9% |
Number of Pages | 111 |
Key Companies Covered | Pfizer, Blink Health, ChemScene, NEON LABORATORIES, and Universal Biologicals |
Segments Covered | By type, By application and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America is likely to hold the largest share in the global carboprost tromethamine market. This is mainly attributed to the increasing demand for contraceptive pills and to treat severe bleeding after childbirth in the United States and Canada. Besides, the presence of major manufacturers in the region ensures the continuous use of carboprost tromethamine. Asia Pacific is projected to offer healthy growth opportunities for the expansion of the carboprost tromethamine market during the forecast period. The two biggest pharma manufacturing countries such as China and India are primarily supporting the growth of the market in the region. China is likely to remain the major revenue contributor in the region whereas, India is projected to showcase rapid growth during the forecast period.
Major players functioning in the global carboprost tromethamine market include:
By Type
By Application Segment
Carboprost Tromethamine
Carboprost Tromethamine
×